Patient characteristics associated with definitive diagnosis of metastatic pancreatic cancer in those initially diagnosed with cancer of unknown primary

White,Larissa Lee; Smith‑Gagen,Julie; Elliott,Leslie; Lu,Minggen

doi:10.3892/mco.2023.2697

Patient characteristics associated with definitive diagnosis of metastatic pancreatic cancer in those initially diagnosed with cancer of unknown primary

Authors:
- Larissa Lee White
- Julie Smith‑Gagen
- Leslie Elliott
- Minggen Lu
View Affiliations

Affiliations: Kaiser Permanente Colorado, Institute for Health Research, Aurora, CO 80014, USA, School of Public Health, University of Nevada, Reno, NV 89557, USA
Published online on: November 6, 2023 https://doi.org/10.3892/mco.2023.2697
Article Number: 101

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer of unknown primary (CUP) and pancreatic cancer (PC) are malignancies associated with poor prognosis. CUP is the fourth most common cause of cancer mortality in the US, and median survival time is 3‑4 months. PC is the third most common cause of cancer mortality in the US, and median survival time for patients with stage 3 or 4 PC is 2‑3 months. The present study aimed to understand the patient characteristics of those initially misdiagnosed with CUP who ultimately received a diagnosis of PC. The present study used 2010‑2015 Surveillance, Epidemiology, and End Results‑Medicare data, a US population‑based cancer registry linked to Medicare health insurance claims. Odds ratios (ORs) and 95% confidence intervals were calculated using two binary logistic regression models to compare the characteristics of patients who received definitive diagnosis between the CUP‑PC group (those with an initial diagnosis of CUP who eventually received a stage 3 or 4 PC diagnosis) and the PC group (those diagnosed with stage 3 or 4 PC only). Approximately 26% of patients who received a definitive diagnosis of metastatic PC started with an initial diagnosis of CUP (n=17,565). The odds of definitive PC diagnosis in patients with CUP were lower for those with a comorbidity score of 0 [OR, 0.85 (95% CI: 0.79, 0.91)] and epithelial/unspecified histology [OR, 0.76 (95% CI: 0.71, 0.82)]. The odds of definitive PC diagnosis in patients with CUP were higher for patients of other race [OR, 1.27 (95% CI: 1.13, 1.43)] compared with white patients. Definitive diagnosis of PC in patients with CUP was lower in patients who were older with fewer or no comorbidities and unspecified histology. The complexity of CUP diagnosis and patient performance status may influence delays in diagnosis to a known primary site.

View Figures

View References

1	National Cancer Institute (NCI). Cancer of unknown primary-health professional version. National Cancer Institute, 2017. https://www.cancer.gov/types/unknown-primary/hp.
2	Pavlidis N and Pentheroudakis G: Cancer of unknown primary site. Lancet. 379:1428–1435. 2012.PubMed/NCBI View Article : Google Scholar
3	Rassy E, Parent P, Lefort F, Boussios S, Baciarello G and Pavlidis N: New rising entities in cancer of unknown primary: Is there a real therapeutic benefit? Crit Rev Oncol Hematol. 147(102882)2020.PubMed/NCBI View Article : Google Scholar
4	Schaffer AL, Pearson SA, Dobbins TA, Er CC, Ward RL and Vajdic CM: Patterns of care and survival after a cancer of unknown primary (CUP) diagnosis: A population-based nested cohort study in Australian government department of Veterans' Affairs clients. Cancer Epidemiol. 39:578–584. 2015.PubMed/NCBI View Article : Google Scholar
5	Moran S, Martinez-Cardús A, Boussios S and Esteller M: Precision medicine based on epigenomics: The paradigm of carcinoma of unknown primary. Nat Rev Clin Oncol. 14:682–694. 2017.PubMed/NCBI View Article : Google Scholar
6	American Cancer Society (ACS). Key statistics for pancreatic cancer. American Cancer Society, 2020. https://www.cancer.org/cancer/pancreatic-cancer/about/key-statistics.html#references.
7	Henrikson NB, Aiello Bowles EJ, Blasi PR, Morrison CC, Nguyen M, Pillarisetty VG and Lin JS: Screening for pancreatic cancer: Updated evidence report and systematic review for the US preventive services task force. JAMA. 322:445–454. 2019.PubMed/NCBI View Article : Google Scholar
8	Khalaf N, El-Serag HB, Abrams HR and Thrift AP: Burden of pancreatic cancer: From epidemiology to practice. Clin Gastroenterol Hepatol. 19:876–884. 2021.PubMed/NCBI View Article : Google Scholar
9	Zhang Q, Zeng L, Chen Y, Lian G, Qian C, Chen S, Li J and Huang K: Pancreatic cancer epidemiology, detection, and management. Gastroenterol Res Pract. 2016(8962321)2016.PubMed/NCBI View Article : Google Scholar
10	Sève P, Mackey J, Sawyer M, Lesimple T, de La Fouchardière C, Broussolle C, Dumontet C and Ray-Coquard I: Impact of clinical practice guidelines on the management for carcinomas of unknown primary site: A controlled ‘before-after’ study. Bull Cancer. 96:E7–E17. 2009.PubMed/NCBI View Article : Google Scholar
11	Pentheroudakis G, Stahel R, Hansen H and Pavlidis N: Heterogeneity in cancer guidelines: Should we eradicate or tolerate? Ann Oncol. 19:2067–2078. 2008.PubMed/NCBI View Article : Google Scholar
12	Smith-Gagen J, Drake CM, White LL and Pinheiro PS: Extent of diagnostic inquiry among a population-based cohort of patients with cancer of unknown primary. Cancer Rep Rev. 3:2019.PubMed/NCBI View Article : Google Scholar
13	Klabunde CN, Warren JL and Legler JM: Assessing comorbidity using claims data: An overview. Med Care. 40 (8 Suppl):IV26–IV35. 2002.PubMed/NCBI View Article : Google Scholar
14	Department of Health Pharmaceutical Oncology Initiative (DHPOI). The impact of patient age on clinical decision-making in oncology. London, UK: Department of Health, 2012.
15	Massarweh NN, Park JO, Bruix J, Yeung RS, Etzioni RB, Symons RG, Baldwin LM and Flum DR: Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma. J Oncol Pract. 7:155–160. 2011.PubMed/NCBI View Article : Google Scholar
16	Schaffer AL, Pearson SA, Perez-Concha O, Dobbins T, Ward RL, van Leeuwen MT, Rhee JJ, Laaksonen MA, Craigen G and Vajdic CM: Diagnostic and health service pathways to diagnosis of cancer-registry notified cancer of unknown primary site (CUP). PLoS One. 15(e0230373)2020.PubMed/NCBI View Article : Google Scholar
17	Jones W, Allardice G, Scott I, Oien K, Brewster D and Morrison DS: Cancers of unknown primary diagnosed during hospitalization: A population-based study. BMC Cancer. 17(85)2017.PubMed/NCBI View Article : Google Scholar
18	Rassy E and Pavlidis N: The currently declining incidence of cancer of unknown primary. Cancer Epidemiol. 61:139–141. 2019.PubMed/NCBI View Article : Google Scholar
19	Pavlidis N, Rassy E and Smith-Gagen J: Cancer of unknown primary: Incidence rates, risk factors and survival among adolescents and young adults. Int J Cancer. 146:1490–1498. 2020.PubMed/NCBI View Article : Google Scholar
20	Noel M and Fiscella K: Disparities in pancreatic cancer treatment and outcomes. Health Equity. 3:532–540. 2019.PubMed/NCBI View Article : Google Scholar
21	Tavakkoli A, Singal AG, Waljee AK, Elmunzer BJ, Pruitt SL, McKey T, Rubenstein JH, Scheiman JM and Murphy CC: Racial disparities and trends in pancreatic cancer incidence and mortality in the United States. Clin Gastroenterol Hepatol. 18:171–178.e10. 2020.PubMed/NCBI View Article : Google Scholar
22	Zhou H, Zhang Y, Wei X, Yang K, Tan W, Qiu Z, Li S, Chen Q, Song Y and Gao S: Racial disparities in pancreatic neuroendocrine tumors survival: A SEER study. Cancer Med. 6:2745–2756. 2017.PubMed/NCBI View Article : Google Scholar
23	Federal Interagency Forum (FIF) on Aging-Related Statistics. Older Americans: Key indicators of well-being. U.S. Government Printing Office, 2015.
24	Rassy E, Labaki C, Chebel R, Boussios S, Smith-Gagen J, Greco FA and Pavlidis N: Systematic review of the CUP trials characteristics and perspectives for next-generation studies. Cancer Treat Rev. 107(102407)2022.PubMed/NCBI View Article : Google Scholar